文献速递妇科

无铂间期与贝伐珠单抗对晚期卵巢癌一线PARP抑制剂维持治疗进展后二线化疗的影响:一项回顾性队列研究

Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study.
PubMed 文献 · Gynecol Oncol · 2025-11-22

这项单中心回顾性研究(2018-2025)纳入74例一线铂类化疗缓解后复发并接受二线治疗的晚期卵巢癌患者,比较一线PARP抑制剂维持期间复发(On PARPi组46例)与未用药复发(Not on PARPi组28例)的结局。On PARPi组二线无进展生存期和总生存期均显著更短,且在铂敏感亚组中无铂间期与分组存在显著交互作用;On PARPi组二线联合贝伐珠单抗可独立改善二线无进展生存期和总生存期。

要点

  • On PARPi组二线无进展生存期7.0个月 vs Not on PARPi组18.0个月(HR 3.51,P<0.001)。
  • On PARPi组总生存期15.1个月 vs Not on PARPi组39.1个月(HR 2.33,P=0.019)。
  • On PARPi组二线贝伐珠单抗独立改善二线无进展生存期(HR 0.22)和总生存期(HR 0.23)。

核心结论

  • 一线PARP抑制剂维持治疗期间疾病进展与后续化疗后更差的结局相关,将贝伐珠单抗纳入二线化疗及维持治疗与生存改善相关。

研究设计与样本

  • 单中心回顾性研究,2018-2025年,纳入一线铂类化疗缓解后复发的晚期卵巢癌患者74例(On PARPi组46例,Not on PARPi组28例)。

主要发现

  • On PARPi组 vs Not on PARPi组:中位二线无进展生存期7.0个月 vs 18.0个月(HR 3.51,P<0.001)。
  • On PARPi组 vs Not on PARPi组:中位总生存期15.1个月 vs 39.1个月(HR 2.33,P=0.019)。
  • 铂敏感亚组(无铂间期≥6个月)中上述差异持续存在。
  • 铂敏感亚组中无铂间期与分组存在显著交互作用(P=0.012),On PARPi组的不利影响在无铂间期≥12个月的患者中最大。
  • On PARPi组中,二线贝伐珠单抗独立改善二线无进展生存期(HR 0.22)和总生存期(HR 0.23)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare second-line (2 L) outcomes between patients with advanced ovarian cancer whose disease relapsed on first-line (1 L) PARP inhibitor (PARPi) maintenance ("On PARPi") and those who were Not on PARPi at relapse ("Not on PARPi"), and to determine the effect of platinum-free interval (PFI) and bevacizumab. METHODS: A single-center retrospective study (2018-2025) was conducted in patients whose disease relapsed after a response to 1 L platinum-based chemotherapy. The endpoints from the start of 2 L therapy were progression-free survival (2 L-PFS) and overall survival (OS). RESULTS: Of 74 patients ("On PARPi" n = 46; "Not on PARPi" n = 28), 2 L-PFS and OS were significantly shorter in the "On PARPi" group compared with the "Not on PARPi" group (median 2 L-PFS 7.0 vs. 18.0 months; HR 3.51, P < 0.001; median OS 15.1 vs. 39.1 months; HR 2.33, P = 0.019). This difference persisted in the platinum-sensitive subgroup (PFI ≥ 6 months). In the platinum-sensitive subgroup, a significant interaction between PFI and group (P = 0.012) confirmed that the detrimental effect of being in the "On PARPi" group was greatest in patients with a PFI ≥ 12 months. For the "On PARPi" group, 2 L bevacizumab independently improved 2 L-PFS (HR 0.22) and OS (HR 0.23). For the responders to 2 L platinum-based chemotherapy, bevacizumab maintenance improved OS compared with PARPi rechallenge (P = 0.0497). CONCLUSION: Disease progression on 1 L PARPi maintenance was associated with poorer outcomes after subsequent chemotherapy. Incorporating bevacizumab into 2 L chemotherapy and maintenance was associated with improved survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hayakawa M, Nakajima H, Harano K, et al. Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study. Gynecol Oncol. 2025. PMID: 41275790. doi:10.1016/j.ygyno.2025.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。